Menu

Pfizer

XALKORI® (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer

, , , ,

XALKORI is the first and only approved biomarker-driven therapy for ROS1-positive advanced NSCLC in the EU Wednesday, August 31, 2016 – “The European Commission’s decision to approve XALKORI for ROS1-positive advanced NSCLC represents an important milestone for patients who previously had limited treatment options” Pfizer Inc. (NYSE:PFE) today announced that the European Commission has approved […]

Pfizer To Acquire Small Molecule Anti-Infective Business From AstraZeneca

, , ,

Strong fit with Pfizer’s existing anti-infective portfolio Pfizer’s focus on infectious disease and expertise in this category will help enable broader access to anti-infective portfolio Expected to enhance near-term revenue growth potential for Pfizer’s Essential Health business August 24, 2016 – Pfizer Inc. (NYSE:PFE) today announced that it has entered into an agreement with AstraZeneca […]

Pfizer To Acquire Medivation

, , , ,

Propels Pfizer into a leading position in oncology Medivation agrees to transaction valued at $81.50 per Medivation share in cash, for a total enterprise value of approximately $14 billion Expected to be immediately accretive to Pfizer’s Adjusted Diluted EPS upon closing, approximately $0.05 accretive in first full year after close with additional accretion and growth […]

FDA Approves TROXYCA® ER (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules CII with Abuse-Deterrent Properties for the Management of Pain

, ,

August 19, 2016 – Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved TROXYCA® ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules, for oral use, CII for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. TROXYCA […]

Pfizer Announces the Publication of Final Results from Two Pivotal Phase 3 Studies of Crisaborole Topical Ointment in Patients with Mild to Moderate Atopic Dermatitis

, , , ,

Phase 3 Data Published in the Journal of the American Academy of Dermatology July 13, 2016 – Pfizer Inc. (NYSE:PFE) announced today the publication of findings from two pivotal Phase 3 studies of investigational crisaborole topical ointment 2% (formerly AN2728) in the online issue of the Journal of the American Academy of Dermatology. “Atopic dermatitis, […]

Pfizer Receives FDA Approval for Prevnar 13® in Adults Age 18 Through 49

, , ,

Prevnar 13 is the only pneumococcal vaccine approved in the U.S. for patients 6 weeks through adulthood July 12, 2016 – Pfizer Inc. (NYSE:PFE) today announced that Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) received U.S. Food and Drug Administration (FDA) approval for an expanded age indication to include adults 18 through 49 […]

Pfizer Announces Positive Top-Line Results From Phase 3 S-TRAC Trial of SUTENT® (sunitinib) as Adjuvant Therapy in Patients at High Risk of Recurrent Renal Cell Carcinoma

, , , ,

S-TRAC is the First RCC Trial of a Tyrosine Kinase Inhibitor to Prolong Disease-Free Survival in the Adjuvant Setting July 8, 2016 – Pfizer Inc. (NYSE:PFE) today announced that the S-TRAC clinical trial (Sunitinib Trial in Adjuvant RenalCancer), a Phase 3 study of SUTENT versus placebo in the adjuvant setting, met its primary endpoint of improving […]

Two Additional Phase 3 Lipid-Lowering Studies of Bococizumab Deliver Positive Topline Results

, , , ,

SPIRE-HR and SPIRE-FH trials met primary endpoints in patients at high and very high risk for cardiovascular events June 28, 2016 – Pfizer Inc. announced two additional Phase 3 bococizumab trials, SPIRE-HR (HighRisk) and SPIRE-FH (Familial Hypercholesterolemia), met their primary endpoint, demonstrating a significant reduction in the percent change from baseline in low-density lipoprotein cholesterol […]

Pfizer Advances Biosimilars Leadership with Investment in a New World-Class Global Biotechnology Center in China

, ,

Pfizer’s state-of-the-art facility will foster the continued development of the biotechnology industry in China, further supporting National healthcare reforms June 27, 2016 – Pfizer Inc. today announced that it will invest approximately USD$350 million in the development of a state-of-the-art Global Biotechnology Center at a ground-breaking ceremony in the Hangzhou Economic Development Area (HEDA) in […]

1 2